Two-thirds of the metastatic myeloma patients in a phase II study were still alive a year after receiving a new combination therapy, compared to slightly more than half of patients receiving a standard monotherapy for the cancer, according to results presented today at the 49th Annual meeting of the American Society of Clinical Oncology in Chicago.
http://www.ajmc.com/conferences/asco-2013/In-Phase-II-Study-Combination-Therapy-Extends-Survival-Reduces-Side-Effects-in-Metastatic-Melanoma-Patients
http://www.ajmc.com/conferences/asco-2013/In-Phase-II-Study-Combination-Therapy-Extends-Survival-Reduces-Side-Effects-in-Metastatic-Melanoma-Patients
No comments:
Post a Comment